Dr Reddy's Laboratories stock in focus as USFDA completes pre-approval inspection at FTO-9 plant
Dr Reddy's Laboratories said the inspection was conducted from October 8 to October 9, 2026. The company stated that it would address the observations within the stipulated timeline.
- Oct 15, 2026,
- Updated Oct 15, 2026 9:12 AM IST
Dr. Reddy's Laboratories Ltd shares will be in focus on Thursday morning after the company disclosed that the United States Food and Drug Administration (USFDA) completed a pre-approval inspection at its FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, and issued a Form 483 with three observations.
In an exchange filing dated October 14, the pharmaceutical company said the inspection was conducted from October 8 to October 9, 2026. The company stated that it would address the observations within the stipulated timeline.
"This is to inform you that the United States Food and Drug Administration (USFDA) completed a Pre-Approval Inspection (PAI) at our FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh," the company said in its filing. It added that it had "been issued a Form 483 with three observations, which we will address within the stipulated timeline."
Dr. Reddy's Laboratories shares closed at Rs 1,214.10 on Wednesday, down 2.06% from the previous close of Rs 1,239.65. The stock's movement on Thursday will be watched following the disclosure.
The company's filing did not specify the nature of the three observations. It also did not provide further details about the observations in the announcement. The company said it would address them within the stipulated timeline.
Dr. Reddy's Laboratories is a major multinational pharmaceutical company based in Hyderabad, India.
Dr. Reddy's Laboratories Ltd shares will be in focus on Thursday morning after the company disclosed that the United States Food and Drug Administration (USFDA) completed a pre-approval inspection at its FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, and issued a Form 483 with three observations.
In an exchange filing dated October 14, the pharmaceutical company said the inspection was conducted from October 8 to October 9, 2026. The company stated that it would address the observations within the stipulated timeline.
"This is to inform you that the United States Food and Drug Administration (USFDA) completed a Pre-Approval Inspection (PAI) at our FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh," the company said in its filing. It added that it had "been issued a Form 483 with three observations, which we will address within the stipulated timeline."
Dr. Reddy's Laboratories shares closed at Rs 1,214.10 on Wednesday, down 2.06% from the previous close of Rs 1,239.65. The stock's movement on Thursday will be watched following the disclosure.
The company's filing did not specify the nature of the three observations. It also did not provide further details about the observations in the announcement. The company said it would address them within the stipulated timeline.
Dr. Reddy's Laboratories is a major multinational pharmaceutical company based in Hyderabad, India.